Anavex Life Sciences (AVXL) Non-Current Assets (2011 - 2019)
Anavex Life Sciences (AVXL) posted Non-Current Assets of $151133.0 for Q2 2019, down 1.56% sequentially from $153529.0 in Q3 2018, and up 188.44% YoY from $52396.0 in Q2 2018.
Anavex Life Sciences (AVXL) Non-Current Assets (2011 - 2019) Analysis & Trends
Anavex Life Sciences has reported Non-Current Assets for 9 years, with the latest figure at $151133.0 in Q2 2019.
- Quarterly Non-Current Assets rose 188.44% year-over-year to $151133.0 in Q2 2019, while the trailing twelve-month figure through Jun 2020 was $151133.0 (down 50.39% YoY) and the FY2018 annual result came in at $153529.0, up 193.02% from the prior year.
- Non-Current Assets fell to $151133.0 in Q2 2019 per AVXL's latest filing, from $153529.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $153529.0 in Q3 2018 and troughed at $1501.0 in Q2 2015.
- A 5-year average of $65323.1 and a median of $52396.0 in 2016 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2015 and 2018: Non-Current Assets slumped 99.87% in 2015, then jumped 193.02% in 2018.
- Over 5 years, Non-Current Assets stood at $1501.0 in 2015, then surged by 3390.74% to $52396.0 in 2016, then changed by 0.0% to $52396.0 in 2017, then surged by 193.02% to $153529.0 in 2018, then declined by 1.56% to $151133.0 in 2019.
- According to Business Quant data, Non-Current Assets over the past three periods registered $151133.0, $153529.0, and $52396.0 for Q2 2019, Q3 2018, and Q2 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 151,133.00 |
| Sep 30, 2018 | 153,529.00 |
| Jun 30, 2018 | 52,396.00 |
| Mar 31, 2018 | 83,339.00 |
| Dec 31, 2017 | 52,396.00 |
| Sep 30, 2017 | 52,396.00 |
| Jun 30, 2017 | 52,396.00 |
| Sep 30, 2016 | 52,396.00 |
| Jun 30, 2015 | 1,501.00 |
| Mar 31, 2015 | 1,749.00 |
| Dec 31, 2014 | 1,998.00 |
| Sep 30, 2014 | 2,247.00 |
| Jun 30, 2014 | 1.12 Mn |
| Mar 31, 2014 | 1.07 Mn |
| Dec 31, 2013 | 2,135.00 |
| Dec 31, 2012 | 111.00 |
| Sep 30, 2012 | 576.00 |
| Jun 30, 2012 | 1,040.00 |
| Mar 31, 2012 | 1,505.00 |
| Sep 30, 2011 | 2,434.00 |